Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

15 questions · 19 findings · 4 reviews · Neonatal

No studies found 14 · 73.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 26.3%High 0 · 0%

Methylxanthine vs placebo or control

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine vs placebo or control

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

High‐dose vs standard‐dose strategies

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity

The review found no eligible studies for this question.

3 findings from 1 review

High‐dose vs standard‐dose strategies

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

The review found no eligible studies for this question.

3 findings from 1 review

'As needed' administration (e.g. based on pain scales) vs 'as scheduled' administration (e.g. a predefined time interval)

Major neurodevelopmental disability in children aged 18 to 24 months or three to five years old ‐ not reported · postoperative pain in neonates

The review found no eligible studies for this question.

1 finding from 1 review